BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: Present and future: Novel treatment for liver cancer. Journal of Gastroenterology and Hepatology 2012;27:862-72. [DOI: 10.1111/j.1440-1746.2012.07096.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Shlomai A. Targeting late SV40 factor: Is the achilles heel of hepatocarcinogenesis revealed? World J Gastroenterol 2012; 18(46): 6709-6711 [PMID: 23239907 DOI: 10.3748/wjg.v18.i46.6709] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016; 22(32): 7289-7300 [PMID: 27621575 DOI: 10.3748/wjg.v22.i32.7289] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 62] [Article Influence: 14.4] [Reference Citation Analysis]
3 Hu B, Xiong Y, Ni R, Wei L, Jiang D, Wang G, Wu D, Xu T, Zhao F, Zhu M. The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol Cell Biochem. 2014;396:175-185. [PMID: 25081333 DOI: 10.1007/s11010-014-2153-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol. 2013;9:2-5. [PMID: 23418846 DOI: 10.1111/ajco.12061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
5 Wu JR, Hu CT, You RI, Ma PL, Pan SM, Lee MC, Wu WS. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One 2015;10:e0114495. [PMID: 25607934 DOI: 10.1371/journal.pone.0114495] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
6 Chan SL. Drug development for hepatocellular carcinoma: knowing the past helps to understand the future. Oncologist. 2014;19:1115-1117. [PMID: 25223461 DOI: 10.1634/theoncologist.2014-0304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
7 Wu JM, Staton CA. Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opin Drug Discov 2012;7:723-43. [PMID: 22716277 DOI: 10.1517/17460441.2012.695774] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
8 Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: A review. Indian J Gastroenterol 2018;37:481-91. [DOI: 10.1007/s12664-018-0915-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
9 Chan SL, Johnson P. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: An Asian perspective: Editorial. Asia-Pacific Journal of Clinical Oncology 2012;8:111-4. [DOI: 10.1111/j.1743-7563.2012.01551.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Chen YC, Chen IS, Huang GJ, Kang CH, Wang KC, Tsao MJ, Pan HW. Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells. Onco Targets Ther 2018;11:1601-16. [PMID: 29606879 DOI: 10.2147/OTT.S147453] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
11 Zhang H, Wang Y, Bai Y, Shao Y, Bai J, Ma Z, Liu Q, Wu S. Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo. Oncotarget 2017;8:16801-10. [PMID: 28187431 DOI: 10.18632/oncotarget.15160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013;7:87-102. [PMID: 23761989 DOI: 10.4137/CMO.S7633] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
13 Buijs N, Oosterink JE, Jessup M, Schierbeek H, Stolz DB, Houdijk AP, Geller DA, van Leeuwen PA. A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1. Angiogenesis 2017;20:557-65. [PMID: 28741166 DOI: 10.1007/s10456-017-9567-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
14 Hu G, Zhai S, Yu S, Huang Z, Gao R. Circular RNA circRHOBTB3 is downregulated in hepatocellular carcinoma and suppresses cell proliferation by inhibiting miR-18a maturation. Infect Agent Cancer 2021;16:48. [PMID: 34187598 DOI: 10.1186/s13027-021-00384-1] [Reference Citation Analysis]
15 Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Chiou YY, Lin HC, Huo TI. Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. Medicine (Baltimore) 2015;94:e1223. [PMID: 26200647 DOI: 10.1097/MD.0000000000001223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Chow AKM, Yau SWL, Ng L. Novel molecular targets in hepatocellular carcinoma. World J Clin Oncol 2020; 11(8): 589-605 [PMID: 32879846 DOI: 10.5306/wjco.v11.i8.589] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Ilamathi M, Senthilkumar S, Prabu P, Panchapakesan S, Sivaramakrishnan V. Formylchromone exhibits salubrious effects against nitrosodiethylamine mediated early hepatocellular carcinogenesis in rats. Chemico-Biological Interactions 2014;219:175-83. [DOI: 10.1016/j.cbi.2014.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Chen WN, Chen JY, Jiao BY, Lin WS, Wu YL, Liu LL, Lin X. Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion. J Virol. 2012;86:13533-13541. [PMID: 23035214 DOI: 10.1128/jvi.02095-12] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
19 Li B, He H, Zhang S, Zhao W, Li N, Shao R. Salmonella typhimurium strain SL7207 induces apoptosis and inhibits the growth of HepG2 hepatoma cells in vitro and in vivo. Acta Pharmaceutica Sinica B 2012;2:562-8. [DOI: 10.1016/j.apsb.2012.10.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
20 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 13.0] [Reference Citation Analysis]
21 Chen Y, Zhou Q, Li X, Wang F, Heist K, Kuick R, Owens SR, Wang TD. Ultrasmall Paramagnetic Iron Oxide Nanoprobe Targeting Epidermal Growth Factor Receptor for In Vivo Magnetic Resonance Imaging of Hepatocellular Carcinoma. Bioconjugate Chem 2017;28:2794-803. [DOI: 10.1021/acs.bioconjchem.7b00501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
22 姚敏, 杨君伶, 蔚丹丹, 严晓娣, 陈洁, 姚登福. sICAM-1和GPC-3 mRNA对肝癌诊断与转移监测的临床价值. 世界华人消化杂志 2012; 20(21): 1927-1932 [DOI: 10.11569/wcjd.v20.i21.1927] [Reference Citation Analysis]
23 Hong JY, Park SH, Park HJ, Lee SK. Anti-proliferative Effect of 15,16-Dihydrotanshinone I Through Cell Cycle Arrest and the Regulation of AMP-activated Protein Kinase/Akt/mTOR and Mitogen-activated Protein Kinase Signaling Pathway in Human Hepatocellular Carcinoma Cells. J Cancer Prev 2018;23:63-9. [PMID: 30003065 DOI: 10.15430/JCP.2018.23.2.63] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ho HK, Chua BT, Wong W, Lim KS, Teo V, Ong HT, Chen X, Zhang W, Hui KM, Go ML, Ullrich A. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma. Mol Oncol 2014;8:1266-77. [PMID: 24839937 DOI: 10.1016/j.molonc.2014.04.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
25 Li X, Wang J, Li W, Huang Z, Fan W, Chen Y, Shen L, Pan T, Wu P, Zhao M. Percutaneous CT-guided radiofrequency ablation for unresectable hepatocellular carcinoma pulmonary metastases. Int J Hyperthermia. 2012;28:721-728. [PMID: 23153217 DOI: 10.3109/02656736.2012.736669] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
26 Bao H, Liu P, Jiang K, Zhang X, Xie L, Wang Z, Gong P. Huaier polysaccharide induces apoptosis in hepatocellular carcinoma cells through p38 MAPK. Oncol Lett 2016;12:1058-66. [PMID: 27446394 DOI: 10.3892/ol.2016.4686] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
27 Wang Q, Liu S, Yang F, Gan L, Yang X, Yang Y. Magnetic alginate microspheres detected by MRI fabricated using microfluidic technique and release behavior of encapsulated dual drugs. Int J Nanomedicine 2017;12:4335-47. [PMID: 28652736 DOI: 10.2147/IJN.S131249] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
29 García-Vilas JA, Medina MÁ. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications. World J Gastroenterol 2018; 24(33): 3695-3708 [PMID: 30197476 DOI: 10.3748/wjg.v24.i33.3695] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
30 Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M, Wang Y. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma. J Ethnopharmacol. 2013;149:601-612. [PMID: 23916858 DOI: 10.1016/j.jep.2013.07.030] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 13.1] [Reference Citation Analysis]
31 Koul A, Bansal MP, Aniqa A, Chaudhary H, Chugh NA. Lycopene enriched tomato extract suppresses chemically induced skin tumorigenesis in mice. International Journal for Vitamin and Nutrition Research 2020;90:493-513. [DOI: 10.1024/0300-9831/a000597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Gupta DK, Singh N, Sahu DK. TGF-β Mediated Crosstalk Between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma. Cancer Growth Metastasis 2014;7:1-8. [PMID: 24741325 DOI: 10.4137/CGM.S14205] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
33 Kuo ZK, Lin MW, Lu IH, Yao HJ, Wu HC, Wang CC, Lin SH, Wu SY, Tong TS, Cheng YC, Yen JH, Ko CH, Chiou SJ, Pan IH, Tseng HW. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. BMC Complement Altern Med 2016;16:277. [PMID: 27502492 DOI: 10.1186/s12906-016-1250-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Khare T, Khare S, Ibdah JA. Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World J Gastrointest Oncol 2017; 9(1): 1-3 [PMID: 28144394 DOI: 10.4251/wjgo.v9.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Korhan P, Erdal E, Kandemiş E, Cokaklı M, Nart D, Yılmaz F, Can A, Atabey N. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One 2014;9:e105278. [PMID: 25148256 DOI: 10.1371/journal.pone.0105278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
36 Chan SL, Wong VW, Qin S, Chan HL. Infection and Cancer: The Case of Hepatitis B. J Clin Oncol. 2016;34:83-90. [PMID: 26578611 DOI: 10.1200/jco.2015.61.5724] [Cited by in Crossref: 81] [Cited by in F6Publishing: 40] [Article Influence: 13.5] [Reference Citation Analysis]
37 Chan SL, Yeo W. Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World J Gastroenterol 2014; 20(12): 3135-3145 [PMID: 24696599 DOI: 10.3748/wjg.v20.i12.3135] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
38 Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. Br J Cancer 2018;118:1162-8. [PMID: 29563636 DOI: 10.1038/s41416-018-0051-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
39 Patel A, Sun W. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future. Curr Treat Options Oncol. 2014;15:380-394. [PMID: 24838298 DOI: 10.1007/s11864-014-0291-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
40 Tong R, Yang B, Xiao H, Peng C, Hu W, Weng X, Cheng S, Du C, Lv Z, Ding C, Zhou L, Xie H, Wu J, Zheng S. KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling. Oncotarget 2017;8:37717-29. [PMID: 28465479 DOI: 10.18632/oncotarget.17145] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
41 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10584-10597 [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
42 Otsuka T, Nakashita S, Yanagita K, Ario K, Kawasoe H, Kawazoe S, Eguchi Y, Mizuta T. Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Diseases 2015;3:68-77. [PMID: 28943609 DOI: 10.3390/diseases3020068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
43 Korhan P, Erdal E, Atabey N. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. Biochem Biophys Res Commun. 2014;450:1304-1312. [PMID: 25058462 DOI: 10.1016/j.bbrc.2014.06.142] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 7.7] [Reference Citation Analysis]
44 Xiu P, Dong XF, Li XP, Li J. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. World J Gastroenterol 2015; 21(27): 8262-8270 [PMID: 26217078 DOI: 10.3748/wjg.v21.i27.8262] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
45 Rani B, Cao Y, Malfettone A, Tomuleasa C, Fabregat I, Giannelli G. Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. World J Gastroenterol 2014; 20(15): 4128-4140 [PMID: 24764651 DOI: 10.3748/wjg.v20.i15.4128] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
46 Palmer DH, Johnson PJ. Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer Metastasis Rev 2015;34:497-509. [DOI: 10.1007/s10555-015-9580-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
47 Wang Q, Xiao A, Liu Y, Zou Q, Zhou Q, Wang H, Yang X, Zheng C, Yang Y, Zhu Y. One-step preparation of nano-in-micro poly(vinyl alcohol) embolic microspheres and used for dual-modal T1/T2-weighted magnetic resonance imaging. Nanomedicine 2018;14:2551-61. [PMID: 30153472 DOI: 10.1016/j.nano.2018.08.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
48 Firempong CK, Zhang HY, Wang Y, Chen J, Cao X, Deng W, Zhou J, Wang Q, Tong SS, Yu J, Xu X. Segetoside I, a plant-derived bisdesmosidic saponin, induces apoptosis in human hepatoma cells in vitro and inhibits tumor growth in vivo. Pharmacol Res 2016;110:101-10. [PMID: 27180010 DOI: 10.1016/j.phrs.2016.04.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
49 Liu J, Shu Y, Zhang Q, Liu B, Xia J, Qiu M, Miao H, Li M, Zhu R. Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells. Oncol Lett 2014;8:1645-51. [PMID: 25202384 DOI: 10.3892/ol.2014.2330] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
50 Yen CJ, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang DC, Schnell D, Hocke J, Loembé AB, Cheng AL. A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2018;7:165-78. [PMID: 29888206 DOI: 10.1159/000486460] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
51 Chan SL, Wong C, Lau CPY, Zhou Q, Hui CWC, Lui VWY, Ma BBY, Chan ATC, Yeo W. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemother Pharmacol 2013;71:1417-25. [DOI: 10.1007/s00280-013-2139-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
52 Yang L, Hu B, Zhang Y, Qiang S, Cai J, Huang W, Gong C, Zhang T, Zhang S, Xu P, Wu X, Liu J. Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma. Med Oncol 2015;32:128. [PMID: 25794490 DOI: 10.1007/s12032-015-0559-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
53 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-012-0233-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
54 Chan SL, Chan AW, Yeo W. Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opinion on Therapeutic Targets 2015;19:973-83. [DOI: 10.1517/14728222.2015.1031109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
55 Ma L, Chua MS, Andrisani O, So S. Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives. World J Gastroenterol 2014; 20(2): 333-345 [PMID: 24574704 DOI: 10.3748/wjg.v20.i2.333] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 59] [Article Influence: 8.7] [Reference Citation Analysis]
56 Delire B, Stärkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest 2015;45:609-23. [PMID: 25832714 DOI: 10.1111/eci.12441] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 17.0] [Reference Citation Analysis]
57 Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Furuta M, Tsunoda T, Miyano S, Kubo M, Aikata H, Ochi H, Kawakami YI, Arihiro K, Ohdan H, Nakagawa H, Chayama K. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol Gastroenterol Hepatol. 2015;1:516-534. [PMID: 28210698 DOI: 10.1016/j.jcmgh.2015.06.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
58 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-11012-10233-11910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]